Low-density lipoprotein apheresis therapy during pregnancy

Area of Science:

• Cardiovascular Medicine
• Reproductive Medicine
• Lipidology

Background:

• Severe hypercholesterolemia and coronary artery disease (CAD) in pregnancy present significant risks to both mother and fetus.
• HMG-CoA reductase inhibitors (statins), the primary agents for low-density lipoprotein (LDL) cholesterol reduction, are contraindicated during pregnancy due to potential teratogenicity.
• Managing lipid disorders in pregnant patients with pre-existing cardiovascular conditions requires alternative therapeutic strategies.

Observation:

• A case study involving a pregnant woman with heterozygous familial hypercholesterolemia and stable coronary artery disease is presented.
• The patient required aggressive LDL cholesterol reduction during pregnancy.
• Conventional lipid-lowering therapies were not suitable for this patient.

Findings:

• Low-density lipoprotein (LDL) apheresis, specifically utilizing heparin-induced extracorporeal LDL precipitation (H-EPSIL), was employed during pregnancy.
• The H-EPSIL procedure was administered safely and demonstrated efficacy in reducing LDL cholesterol levels.
• The treatment successfully managed hypercholesterolemia without adverse effects on the mother or fetus.

Implications:

• Heparin-induced extracorporeal LDL precipitation (H-EPSIL) represents a viable and effective therapeutic option for managing severe hypercholesterolemia in pregnant patients with coronary artery disease.
• This case highlights the potential of LDL apheresis as a safe alternative when statins cannot be used.
• Further research into LDL apheresis techniques during pregnancy may expand treatment options for high-risk cardiovascular patients.